Seismyc DETECT. DECODE. TRADE. LIVE Pulse
← All stories
Markets 1 sources

Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure

Covered by 1 source · 1 article

Covered by
Yahoo

All coverage

Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure
Yahoo Finance News Sep 12, 10:48 UTC

Jim Cramer Weighs Amgen (AMGN) After Novartis Trial Failure

More top stories

14m ago Intel-Backed Altera Prepares IPO That Could Raise More Than $2B 18m ago Hit Frequency vs Volatility: 5 Casinos Sorted by Session Feel 19m ago Oracle Stock Jumps as AI Cloud Backlog Reaches $664B 32m ago Morgan Stanley likes Coinbase's future, not its stock 35m ago Amazon’s bestselling tool kit that comes with 126 pieces is on sale for $50 38m ago Crypto researcher urges $XRP holders to double-check destination tags in transfers